drugset
Drugs / Efpeglenatide
last change Apr 2026 re-read 2 minutes ago

Efpeglenatide

also known as HM11260C · SAR439977 · Langlenatide

Peptide targets GLP1R via activation

Developed for
type 2 diabetes mellitus · obesity disorder · diabetes mellitus
Investigated by
Hanmi Pharmaceutical Company Limited · Sanofi

Trials 12 · a red edge is where a trial was stopped

today NCT07379333 · Ph 3 NCT06174779 · Ph 3 NCT03770728 · Ph 3 NCT03713684 · Ph 3 NCT03684642 · Ph 3 NCT03496298 · Ph 3 NCT03353350 · Ph 3 NCT02081118 · Ph 2 NCT02075281 · Ph 2 NCT02057172 · Ph 2 NCT02059564 · Ph 1 NCT01093729 · Ph 1
2010201120122013201420152016201720182019202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT02059564 Dec 2013 → Oct 2014 diabetes mellitus Hanmi Pharmaceutical Company Limited Unknown No outcome recorded
Phase 1 NCT01093729 Feb → Oct 2010 — Hanmi Pharmaceutical Company Limited Completed No outcome recorded
Phase 23 trials
Phase 2 NCT02081118 Feb 2014 → Mar 2015 type 2 diabetes mellitus Hanmi Pharmaceutical Company Limited Completed No outcome recorded
Phase 2 NCT02075281 Feb 2014 → Jan 2015 obesity disorder Hanmi Pharmaceutical Company Limited Completed No outcome recorded
Phase 2 NCT02057172 Jan → Oct 2014 type 2 diabetes mellitus Hanmi Pharmaceutical Company Limited Completed No outcome recorded
Phase 37 trials
Phase 3 NCT07379333 Apr 2026 → Nov 2027 expected type 2 diabetes mellitus Hanmi Pharmaceutical Company Limited Recruiting No outcome recorded
Phase 3 NCT06174779 Jan 2024 → Aug 2025 obesity disorder Hanmi Pharmaceutical Company Limited Completed No outcome recorded
Phase 3 NCT03770728 Aug 2019 → Nov 2020 type 2 diabetes mellitus Sanofi Terminated No outcome recorded
Phase 3 NCT03713684 Nov 2018 → Nov 2020 type 2 diabetes mellitus Sanofi Terminated No outcome recorded
Phase 3 NCT03684642 Sep 2018 → Oct 2020 type 2 diabetes mellitus Sanofi Terminated No outcome recorded
Phase 3 NCT03496298 Apr 2018 → Dec 2020 type 2 diabetes mellitus Sanofi Terminated No outcome recorded
Phase 3 NCT03353350 Dec 2017 → Jan 2020 type 2 diabetes mellitus Hanmi Pharmaceutical Company Limited Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT01452451 Comparator Dec 2011 → Jun 2013 diabetes mellitus Hanmi Pharmaceutical Company Limited Completed No outcome recorded

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 14 sources stand behind the page.

FieldValueCited text
Known as Efpeglenatide ClinicalTrials.gov intervention name — accepted as the source's own label NCT03496298 ↗
4

NCT03684642 ↗

NCT03713684 ↗

NCT03353350 ↗

NCT03770728 ↗
Known as HM11260C ClinicalTrials.gov intervention name — accepted as the source's own label NCT02081118 ↗
7

NCT02057172 ↗

NCT07379333 ↗

NCT01093729 ↗

NCT01452451 ↗

NCT06174779 ↗

NCT02075281 ↗

NCT02059564 ↗
Known as Langlenatide ChEMBL registry synonym — accepted as the source's own label CHEMBL4650470 ↗
Known as SAR439977 “Drug: efpeglenatide (SAR439977)” NCT03353350 ↗
3

“Drug: Efpeglenatide SAR439977” NCT03770728 ↗

“Efpeglenatide (SAR439977)” NCT03496298 ↗

“Efpeglenatide SAR439977” NCT03713684 ↗
Action Activate “Glucagon-like peptide 1 receptor agonist” CHEMBL4650470 ↗
1

“the GLP 1 Agonist HM11260C” NCT01452451 ↗
Modality Peptide “Glucagon-like peptide-1 analogue” NCT02075281 ↗
Route Subcutaneous “After Subcutaneous Administration” NCT01093729 ↗
Target GLP1R “Glucagon-like peptide 1 receptor agonist” CHEMBL4650470 ↗